Skip to main content

Table 2 Effects of liguzinediol on echocardiographic parameters in MI rats

From: The protective effects of liguzinediol on congestive heart failure induced by myocardial infarction and its relative mechanism

Parameters Dose (mg/kg) Sham MI Captopril Digoxin Liguzinediol
10 0.032 5 10 20
EF (%) Before 74.88 ± 5.35 43.49 ± 10.42** 49.46 ± 9.18** 42.51 ± 4.71** 48.13 ± 9.59** 47.18 ± 10.39** 46.73 ± 9.84**
After 74.75 ± 3.35 40.41 ± 12.21** 56.96 ± 13.57#** 49.37 ± 8.7** 51.9 ± 10.47#** 54.01 ± 8.96#** 54.34 ± 7.06##**
D-value − 0.13 ± 4.41 − 3.08 ± 11.41 7.50 ± 8.02#* 6.87 ± 7.01#* 3.77 ± 5.91 6.84 ± 6.77#* 7.60 ± 8.88#*
LVFS (%) Before 45.1 ± 4.81 22.51 ± 6.21** 26.21 ± 5.65 21.95 ± 2.75** 25.43 ± 5.81** 24.83 ± 6.09** 24.5 ± 5.96**
After 45.11 ± 3.07 21.08 ± 7.13** 31.82 ± 9.03##** 26.55 ± 5.65** 28.16 ± 6.47#** 29.48 ± 5.69##** 29.62 ± 4.71##**
D-value 0.02 ± 4.31 − 1.42 ± 6.81 5.61 ± 5.27#* 4.61 ± 4.61#* 2.73 ± 3.56 4.65 ± 4.16#* 5.11 ± 5.60#*
LVEDd (μl) Before 246.41 ± 33.12 369.15 ± 72.01** 329.81 ± 105.51* 341.19 ± 45.66* 343.17 ± 77.95** 323.75 ± 54.36** 319.9 ± 88.49*
After 313.72 ± 64.81 499.06 ± 110.08** 409.29 ± 142.54 458.63 ± 48.54 450.5 ± 94.66** 445.75 ± 143.86* 425.03 ± 69.42**
D-value 67.30 ± 69.74 129.91 ± 97.63 79.48 ± 102.45 117.44 ± 55.89 107.32 ± 60.47 122.00 ± 109.33 105.13 ± 64.13
LVEDs (μl) Before 62.56 ± 18.13 214.87 ± 77.82** 178.92 ± 78.14** 180.27 ± 37.10** 183.64 ± 72.31** 173.44 ± 55.05** 174.88 ± 67.36**
After 79.20 ± 24.57 306.92 ± 126.73** 186.91 ± 113.1##** 227.96 ± 39.82** 223.55 ± 97.08** 214.27 ± 117.18** 196.44 ± 55.52#**
D-value 16.65 ± 17.50 92.05 ± 109.06* 7.99 ± 65.86 47.69 ± 33.76 39.91 ± 62.72 40.83 ± 69.18 21.55 ± 40.55
SV (μl) Before 183.86 ± 23.50 154.28 ± 34.94* 150.89 ± 32.99* 160.91 ± 58.60* 159.53 ± 23.84* 150.31 ± 33.73* 145.01 ± 36.39*
After 234.52 ± 42.30 192.14 ± 39.13* 222.38 ± 54.3 230.67 ± 40.01# 226.94 ± 37.46 231.49 ± 40.72# 228.59 ± 33.71#
D-value 47.66 ± 62.07 37.86 ± 48.96* 71.49 ± 49.23 69.75 ± 47.24 67.41 ± 27.00 81.17 ± 52.41 83.58 ± 46.71#
CO (ml/min) Before 78.39 ± 17.95 56.76 ± 13.26** 61.93 ± 19.52 68.02 ± 29.40* 62.7 ± 10.2* 60.63 ± 19.4* 64.29 ± 17.28
After 99.69 ± 18.28** 70.41 ± 12.16** 91.11 ± 26.4# 92.57 ± 28.01# 91.32 ± 16.46## 95.77 ± 22.52## 100.41 ± 15.71##
D-value 19.76 ± 24.93 13.65 ± 18.81 29.18 ± 22.59 24.54 ± 19.31 28.62 ± 13.37 35.15 ± 20.47# 36.11 ± 19.31#
  1. Sham, sham-operated; MI, myocardial infarction; Before, before administration; After, after administration for 8 weeks; D-value = after–before; EF, ejection fraction; LVFS, left ventricular fractional shortening; LVEDd, LV end-diastolic dimension; LVEDs, LV end-systolic dimension; SV, stroke volum; CO, cardiac output, CO = SV × HR (heart rate)
  2. Data are shown as the mean ± SD (n = 10). *P < 0.05, **P < 0.01, compared to Sham group; #P < 0.05, ##P < 0.01, compared to MI group